Validity of DSM-IV ADHD Subtypes in a Community Sample

描述（由申请人提供）：拟议的项目将测试 使用多个DSM-IV ADHD亚型的内部和外部效度 收敛方法为了实现这些目标，ADHD症状的测量， 功能障碍、智力/学术成就、其他 精神病理学和神经心理学功能将被管理到 从最初的11 000名非转诊儿童中选出以下群体： 150名先证者为混合亚型，150名为多动/冲动型 亚型，150与疏忽亚型谁也表现出显着的症状 缓慢的认知克里思（SCT），和150与疏忽亚型，没有 显着的SCT症状，以及150名儿童的比较样本， 不符合任何ADHD亚型标准的SCT显著升高， 150名无ADHD或显著SCT症状的儿童。信度和内部 DSM-IV亚型的有效性将通过检查评估者间 一致性和进行探索性和验证性的因素和集群 分析。每年将获得纵向跟踪措施， 有利于分析的时间稳定性和发展过程中， DSM-IV症状和亚型。DSM-IV亚型的诊断效度 如果每个亚型与显著性相关， 其他功能领域的损害。区分效度 将通过比较子类型的功能度量来评估子类型 损害和其他临床相关因素，并通过检测SCT的症状 识别在诊断上有意义的个体子集， 疏忽亚型检查遗传和非遗传病因 将评估产前/围产期并发症，并将 从所有先证者，他们的父母，和生物学上最接近的兄弟姐妹中获得 先证者的年龄，便于直接测试不同的病因， 使用遗传连锁和关联分析的ADHD亚型。最后所有 参与者将完成一系列广泛的神经认知测量， 认知/注意力亚型之间的差异表现测试 的措施和贡献的SOT这些差异。预计在 使用大型社区样本，纵向评估， 病因学信息设计和广泛的神经认知电池 措施将提供有关最佳疾病分类学的重要新信息， ADHD

DESCRIPTION (provided by applicant): The proposed project will test the internal and external validity of subtypes of DSM-IV ADHD using multiple converging methods. To accomplish these objectives, measures of ADHD symptoms, functional impairment, intellectual/academic achievement, other psychopathology, and neuropsychological functioning will be administered to the following groups selected from an initial pool of 11,000 non-referred children: 150 probands with the combined subtype, 150 with the hyperactive/impulsive subtype, 150 with the inattentive subtype who also exhibit significant symptoms of sluggish cognitive tempo (SCT), and 150 with the inattentive subtype without significant SCT symptoms, as well as comparison samples of 150 children with significant elevations of SCT who do not meet criteria for any ADHD subtype and 150 children without ADHD or significant SCT symptoms. Reliability and internal validity of the DSM-IV subtypes will be tested by examining inter-rater agreement and conducting exploratory and confirmatory factor and cluster analyses. Longitudinal follow-up measures will be obtained annually to facilitate analyses of the temporal stability and developmental course of the DSM-IV symptoms and subtypes. The diagnostic validity of the DSM-IV subtypes will be examined by testing if each subtype is associated with significant impairment in other domains of functioning. Discriminant validity among the subtypes will be evaluated by comparing subtypes on measures of functional impairment and other clinical correlates, and by testing if symptoms of SCT identify a diagnostically meaningful subset of individuals within the inattentive subtype. To examine both genetic and non-genetic etiological factors, pre/perinatal complications will be assessed and DNA samples will be obtained from all probands, their parents, and the biological sibling closest in age to the proband, facilitating a direct test for differential etiology of ADHD subtypes using genetic linkage and association analyses. Finally, all participants will complete an extensive battery of neurocognitive measures to test for differential performance among the subtypes on cognitive/attentional measures and the contribution of SOT to these differences. It is expected that the use of a large community sample, a longitudinal assessment, an etiologically informative design, and a broad battery of neurocognitive measures will provide important new information regarding the optimal nosology of ADHD.